drugset / Trial / NCT03150602

A Pralatrexate Study in Asian Patients With Peripheral T-cell Lymphoma After Prior Therapy

NCT03150602

Phase 4 Unknown 22 enrolled Taiwan Mundipharma Pharmaceuticals Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This study is to evaluate the objective response rate to pralatrexate in Asian PTCL patients after prior treatment failure, as determined by independent imaging reviewer(s) using international workshop lymphoma response criteria (IWC)

Timeline

Start
2016-08-30
Primary completion
2020-12-31
Completion
2020-12-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Pralatrexate Other / unclassified 20 mg/m2 Intravenous
Subject Pralatrexate Other / unclassified 30 mg/m2 Intravenous